Device Trial Radar · NCT06978907
Evaluation of the Efficacy and Safety of Lactobacillus Crispatus M247 (Crispact®) With Vaginal Laser Therapy in Menopausal Women With Atrophic Vulvovaginitis (VVA)
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jul 1, 2025
Primary completion
Nov 27, 2025
Study completion Dec 9, 2025
Sponsor
- Lead sponsor
- Liaquat University of Medical & Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Università degli Studi dell'Insubria
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, controlled, prospective, multicenter study aims to evaluate the efficacy and safety of Lactobacillus crispatus M247 in combination with vaginal laser therapy for improving vaginal microbiota composition and reducing genitourinary symptoms in menopausal women with atrophic vulvovaginitis (VVA). Participants will be randomized into two groups: one receiving laser therapy alone and the other receiving laser therapy combined with daily administration of the probiotic Lactobacillus crispatus M247 (Crispact®). Primary outcomes include changes in genitourinary symptoms assessed using a validated vulvovaginal symptom questionnaire and evaluation of safety. Secondary outcomes include changes in vaginal microbiota composition.
Conditions
- Atrophic Vulvovaginitis
Interventions
Monnalisa Touch® Laser TherapyDevice
Monnalisa Touch® laser therapy is a non-ablative fractional CO2 laser applied to the vaginal mucosa to promote tissue regeneration and maintain vaginal health. Participants in this group will receive three sessions of laser therapy, one session every 30 days.
Monnalisa Touch® Laser Therapy + Lactobacillus crispatus M247 (Crispact®)Combination product
Participants in this group will receive three sessions of Monnalisa Touch® laser therapy, one session every 30 days, along with daily administration of Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU, taken orally for three months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Genitourinary SymptomsTime frame: Baseline (T0) to Month 3 (M3).
- Safety AssessmentTime frame: Baseline (T0) to Month 3 (M3).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Villa Margherita Clinic
Roma, Italy
Hospital State of Republic of San Marino
San Mariano, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.